Leukemia, Myelogenous, Chronic, BCR-ABL Positive: all 982 studies
Page 9 of 10. Open to participants first (109), then studies with results posted, then the rest; newest registration first within each.
- Nilotinib as First-line Treatment of Ph+ CML in Early Chronic PhaseCompletedNCT00481052Phase 2
- Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid LeukemiaCompletedNCT00478985Not applicable
- Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative TherapyCompletedNCT00469729Phase 2/3
- Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic LeukemiaTerminatedNCT00464113Phase 1
- Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on ImatinibTerminatedNCT00461929Phase 4
- Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological MalignanciesCompletedNCT00460694Phase 1/2
- Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic TransplantationCompletedNCT00460629Phase 1/2
- GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00459212Phase 1
- Safety Assessment of a Multipeptide-gene Vaccine in CMLCompletedNCT00455221Phase 1
- Autologous Stem Cell Transplants for Chronic Myelogenous LeukemiaWithdrawnNCT00446173Phase 2
- Registration of Children With CML and Treatment With ImatinibStatus unknownNCT00445822
- Natural Killer Index From Hematopoietic Stem Cell GraftCompletedNCT00435864Not applicable
- Natural History Study of Patients With Chronic Myelogenous LeukemiaCompletedNCT00429910
- Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)CompletedNCT00428909Phase 1
- Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or IntolerantNo longer availableNCT00413270
- Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid LeukaemiaCompletedNCT00390897Phase 4
- A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALLCompletedNCT00384228Phase 1/2
- Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other DiseasesCompletedNCT00357708Phase 1
- Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
- Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic TransplantCompletedNCT00354120Phase 2/3
- Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00352677Phase 1
- Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other DiseasesCompletedNCT00351975Phase 1
- Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALLWithdrawnNCT00349518Phase 2/3
- Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00345826Phase 1
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
- Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in JapanCompletedNCT00337454Phase 1/2
- PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL TherapyStatus unknownNCT00335868Phase 2
- Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00331513Phase 1
- Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood TransplantationStatus unknownNCT00328237Phase 2
- Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic PhaseStatus unknownNCT00327262Phase 3
- Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic PhaseWithdrawnNCT00324077Phase 1
- Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateCompletedNCT00316953Phase 1
- T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell TransplantationTerminatedNCT00306332Phase 3
- Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First RemissionCompletedNCT00305708Phase 1/2
- PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CMLCompletedNCT00303290Phase 1
- Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid LeukemiaNo longer availableNCT00302016
- 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic SyndromesCompletedNCT00301938Phase 1
- SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaTerminatedNCT00301769Phase 1
- Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00301093Phase 1
- A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib MesylateCompletedNCT00298987Phase 2
- Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib TherapyStatus unknownNCT00297570Phase 3
- Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative DisordersCompletedNCT00293410Phase 1
- Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)CompletedNCT00285259Phase 2
- Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory AnemiaCompletedNCT00278330Phase 1
- Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
- Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic MalignanciesCompletedNCT00270881Phase 1/2
- Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate TherapyCompletedNCT00264160Phase 2/3
- Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00258271Phase 1
- Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)CompletedNCT00257647
- Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic MalignanciesCompletedNCT00246662Phase 1
- Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)CompletedNCT00237120Phase 3
- G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete RemissionCompletedNCT00233961Phase 1
- Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous PatientsTerminatedNCT00219765Phase 1/2
- Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 YearsCompletedNCT00219752Phase 2
- STI571 ProspectIve RandomIzed Trial: SPIRITCompletedNCT00219739Phase 3
- Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell TransplantationCompletedNCT00219726Phase 2
- Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or LeukemiaCompletedNCT00217412Phase 1
- Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)Status unknownNCT00199186Phase 2
- Haploidentical Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00186823Phase 3
- Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic MalignanciesCompletedNCT00186342Not applicable
- Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)TerminatedNCT00185523
- Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])CompletedNCT00179764Not applicable
- Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)CompletedNCT00171899Phase 4
- Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) LeukemiaCompletedNCT00167167Not applicable
- Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid LeukemiaWithdrawnNCT00162513Phase 1/2
- Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in IsraelCompletedNCT00159003
- Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00152139Phase 3
- AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One YearStatus unknownNCT00146913Phase 2
- Haploidentical Stem Cell Transplant for Treatment Refractory Hematological MalignanciesCompletedNCT00145613Phase 2
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
- Stem Cell Transplantation as Immunotherapy for Hematologic MalignanciesCompletedNCT00143559Phase 2
- Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00119340Phase 1/2
- BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib MesylateStatus unknownNCT00112775Phase 2
- MK0457 in Patients With Leukemia (0457-003)CompletedNCT00111683Phase 1
- Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT00110058Phase 2
- BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT00103701Phase 1
- Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00101595Phase 2
- Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaTerminatedNCT00101231Phase 1
- Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00101088Phase 1
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateCompletedNCT00100997Phase 1
- SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic SyndromesCompletedNCT00098826Phase 1
- Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesCompletedNCT00098423Phase 1
- Investigation of Clofarabine in Acute LeukemiasCompletedNCT00098033Phase 2
- XK469R in Treating Patients With Refractory Hematologic CancerCompletedNCT00095797Phase 1
- Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid TumorsCompletedNCT00093821Phase 1
- Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib MesylateCompletedNCT00093639Phase 1/2
- Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood CancersCompletedNCT00089596Phase 1/2
- PTK 787 and Gleevec in Patients With AML, AMM, and CML-BPCompletedNCT00088231Phase 1/2
- Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00087204Phase 1
- CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic PhaseCompletedNCT00084916Phase 2
- Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00081926Phase 4
- Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous LeukemiaCompletedNCT00079313Phase 2
- Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2
- Bortezomib in Treating Young Patients With Refractory or Recurrent LeukemiaCompletedNCT00077467Phase 1
- 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic MalignanciesCompletedNCT00077181Phase 1
- Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial TreatmentCompletedNCT00072579Phase 2
- Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00066326Phase 1
- BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib MesylateCompletedNCT00064233Phase 1
- Experimental Bone Marrow Transplant ProtocolCompletedNCT00061581Phase 2
- Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1